70837 Origami™ B(DE3) Competent Cells - Novagen

View Products on Sigmaaldrich.com
70837
View Pricing & Availability

Overview

Replacement Information

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
70837-3
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 0.4 ml
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      70837-4
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Glass bottle 1 ml
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewOrigami™ B host strains carry the same mutations in trxB and gor as the original Origami strains, except that they are derived from a lacZY mutant of BL21 to enable precise control of expression levels by adjusting the concentration of IPTG. Thus the Origami B strains combine the desirable characteristics of BL21, Tuner™, and Origami strains in one strain background. The mutations in trxB and gor are selectable on kanamycin and tetracycline, respectively; therefore, these strains cannot be used with plasmids that can only selected with kanamycin or tetracycline. These strains also include the lon and ompT deficiences of BL21, which increase protein stability.

          DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.
          Genotype: F- ompT hsdSB(rB- mB-) gal dcm lacY1 ahpC (DE3) gor522:: Tn10 trxB (KanR, TetR)


          This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges MilliporeSigma to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.




          This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the 'EMD Product') requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: licensing@milliporesigma.com.
          Catalogue Number70837
          Brand Family Novagen®
          References
          Product Information
          Components
          Guaranteed efficiencyGuaranteed efficiency: > 2 x 10⁶ cfu/μg
          Quality LevelMQ100
          Applications
          Biological Information
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Dry Ice Only
          Toxicity Multiple Toxicity Values, refer to MSDS
          Storage ≤ -70°C
          Do not freeze Ok to freeze
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Origami™ B(DE3) Competent Cells - Novagen SDS

          Title

          Safety Data Sheet (SDS) 

          Origami™ B(DE3) Competent Cells - Novagen Certificates of Analysis

          TitleLot Number
          70837

          Citations

          Title
        • Chikako Fukuda, Shigeyuki Kawai and Kousaku Murata. (2007) NADP(H) Phosphatase Activities of Archaeal Inositol Monophosphatase and Eubacterial 3'-Phosphoadenosine 5'-Phosphate Phosphatase. Applied and Enviornmental Microbiology 73, 5447-5452.
        • R. Jeremy Johnson, Shawn R. Lin and Ronald T. Raines. (2007) Genetic selection reveals the role of a buried, conserved polar residue. Protein Science 16, 1609-1616.
        • Gang Li, et al. (2005) N-Terminal insertion and C-terminal ankyrin-like repeats of α-latrotoxin are critical for Ca2+-dependent exocytosis. Journal of Neuroscience 25, 10188-10197.
        • HaJeung Park, Floyd G. Adsit and Jeffrey C. Boyington. (2005) The 1.4 A crystal structure of the human oxidized low density lipoprotein receptor LOX-1. Journal of Biological Chemistry 280, 13593-13599.
        • Naoko Tsuneyoshi, et al. (2005) The functional and structural properties of MD-2 required for lipopolysaccharide binding are absent in MD-11. Journal of Immunology 174, 340-344.
        • Li Wang, Gang Li and Shuzo Sugita. (2005) A central kinase domain of yype I phosphatidylinositol phosphate kinases is sufficient to prime exocytosis: isoform secificity and its underlying mechanism. Journal of Biological Chemistry 280, 16522-16527.
        • M. Claire H. Holland and John D. Lambris. (2004) A Functional C5a anaphylatoxin receptor in a teleost species. Journal of Immunology 172, 349-355.
        • M. Miertzschke and T. Greiner-Stoffele. (2003) The xthA gene product of Archaeoglobus fulgidus is an unspecific DNase. European Journal of Biochemistry 270, 1838-1849.
        • Atsushi Kodan, Hiroyuki Kuroda and Fukumi Sakai. (2002) A stilbene synthase from Japanese red pine (Pinus densiflora): Implications for phytoalexin accumulation and down-regulation of flavonoid biosynthesis. Procedings of the National Academy of Science 99, 3335-3339.
        • Related Products & Applications

          Related Products

          Catalog Number Description  
          70836 Origami™ B Competent Cells - Novagen Show Pricing & Availability
          70839 Origami™ B(DE3)pLysS Competent Cells - Novagen Show Pricing & Availability
          70911 Origami™ B Competent Cell Set - Novagen Show Pricing & Availability

          Related Products By: Brand Facete

          Categories

          Life Science Research > Genomic Analysis > Transfection and Protein Expression > Bacterial Expression > Competent Cells for Expression